Local injections of corticotropin releasing factor reduce doxorubicin- induced acute inflammation in the eyelid

Investigative Ophthalmology and Visual Science

Volumn 38, Issue 5, 1997, Pages 834-841

  McLoon, Linda Kirschen ^a   Wirtschafter, Jonathan ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

blepharospasm; corticotropin releasing factor; doxorubicin; hemifacial spasm; inflammation; myotoxicity; orbicularis oculi

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLEPHAROSPASM; BLOOD VESSEL PERMEABILITY; DRUG EFFECT; EYELID EDEMA; HEMIFACIAL SPASM; INFLAMMATORY INFILTRATE; INJECTION SITE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SKIN INJURY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEPHARITIS; CORTICOTROPIN-RELEASING HORMONE; DENERVATION; DISEASE MODELS, ANIMAL; DOXORUBICIN; EYELIDS; FACIAL MUSCLES; INJECTIONS; MACACA FASCICULARIS; OCULOMOTOR MUSCLES; RABBITS;

EID: 0030998754     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Wirtschafter JD. Clinical doxorubicin chernomyectomy: An experimental treatment for muscle spasms. Ophthalmology. 1991;98:357-366.
2. McLoon LK, Wirtschafter JD, Cameron JD. Muscle loss from doxorubicin injections into the eyelids of a patient with blepharospasm. Am J Ophthalmol. 1993;116:646-648.
3. Wirtschafter JD. Chemomyectomy of the orbicularis oculi muscles for the treatment of localized hemifacial spasm. J Neuroophihalmol. 1994;14:199-204.
4. McLoon LK, Bauer G, Wirtschafter JD. Quantification of muscle loss in the doxorubicin treated orbicularis oculi of the monkey. Invest Ophthalmol Vis Sci. 1991;32:1667-1673.
5. Tidball JG. Inflammatory cell response to acute muscle injury. Med Sci Sports Exerc. 1995;27:1022-1032.
6. Orimo S, Hiyamuta E, Arahata K, Sugita H. Analysis of inflammatory cells and complement C3 in bupivacaine-induced myonecrosis. Muscle Nerve. 1991;14:515-520.
7. Cotran RS, Kumar V, Robbins SL. Inflammation and repair. In: Pathologic Basis of Disease. 4th ed. Philadelphia: WB Saunders;1989:39-71.
8. Thomas HA, Ling N, Wei ET. CRF and related peptides as anti-inflammatory agonists. Ann N Y Acad Sci. 1993;697:219-228.
9. Kiang JG, Wei ET. Corticotropin releasing factor inhibits thermal injury. J Pharmacol Exp Ther. 1987;243:517-520.
10. Gao GC, Dashwood MR, Wei ET. Corticotropin releasing factor inhibition of substance P-induced vascular leakage in rats: Possible sites of action. Peptides. 1991;12:639-644.
11. Wei ET, Gao GC. Corticotropin releasing factor: An inhibitor of vascular leakage in rat skeletal muscle and brain cortex after injury. Regul Pept. 1991;33:93-104.
12. Serda SM, Wei ET. Epinephrine-induced pulmonary oedema in rats is inhibited by Corticotropin releasing factor. Pharmacol Res. 1992;26:85-91.
13. Chowdry HS, Larsen PJ, Harbuz MS, Lightman SL, Jessop DS. Endogenous substance P inhibits the expression of Corticotropin releasing hormone during a chronic inflammatory stress. Life Sci. 1995;57:2021-2029.
14. Wei ET, Gao GC, Thomas HA. Peripheral anti-inflammatory actions of Corticotropin releasing factor. Ciba Found Symp. 1993;172:258-276.
15. DoroshowJH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 1983;43:460-472.
16. Lee V, Randhawa AK, Singal PK. Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals. Am J Physiol. 1991;261:H989-H995.
17. McLoon LK, Luo XX, Wirtschafter JD. Acute morphologic changes in orbicularis oculi muscle after doxorubicin injection into rabbit eyelid. Muscle Nerve. 1993;16:737-743.
18. Saria A, Lundberg JM. Evans blue fluorescence: Quantitative and morphological evaluation of vascular permeability in animal tissues. J Neurosci Methods. 1983;8:41-49.
19. McLoon LK, Ozel B, Wirtschafter JD. Cyclosporin protects the eyelid skin from injury after injection of doxorubicin. Invest Ophthalmol Vis Sci. 1995;36:1433-1440.
20. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J. 1994;8:504-512.
21. McLennan IS. Resident macrophages (ED2- and ED3-positive) do not phagocytose degenerating rat skeletal muscle fibers. Cell Tissue Res. 1993;272:193-196.
22. Wei ET, Kiang JG, Buchan P, Smith TW. Corticotropin releasing factor inhibits neurogenic plasma extravasation in the rat paw. J Pharmacol Exp Ther. 1986;238:783-787.
23. Sternberg EM, Hill HM, Chrousos GP, et al. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis Rats. Proc Natl Acad Sci USA. 1989;86:2374-2378.
24. Calogero AE, Sternberg EM, Badgy G, et al. Neurotransmitter-induced hypothalamic-pituitary-adrenal axis responsiveness is defective in inflammatory disease-susceptible Lewis rats. In vivo and in vitro studies suggesting globally defective hypothalamic secretion of corticotropin-releasing hormone. Neuroendocrinology. 1992;55:600-608.
25. Poree LR, Dickenson AH, Wei ET. Corticotropin releasing factor inhibits the response of trigeminal neurons to noxious heat. Brain Res. 1989;502:349-355.
26. Leu SJC, Singh VK. Stimulation of interleukin-6 production by Corticotropin releasing factor. Cell Immunol 1992;143:220-227.
27. Rudolph R, Stein RS, Pattillo RA. Skin ulcers due to Adriamycin. Cancer. 1976;37:1087-1094.
28. Bowers DB, Lynch JB. Adriamycin extravasation. Plast Reconstr Surg. 1978;61:686-692.
29. Sonneveld P, Wassenaar H, Nooter K. Long persistence of doxorubicin in human skin after extravasation. Cancer Treat Rep. 1984;68:895-896.
30. McLoon LK, Wirtschafter JD. Doxorubicin chemomyectomy in orbicularis oculi: increasing drug infiltration at the injection site. Curr Eye Res. 1996;5:883-889.